3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
6
Lymphoma, Mantle-Cell
5
Lymphoma, Non-Hodgkin
4
Multiple Myeloma
3
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Leukemia, B-Cell
2
Waldenstrom Macroglobulinemia
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Follicular
1
Leukemia, Prolymphocytic
1
Leukemia, Hairy Cell
1
Leukemia
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Chromosome 17 deletion
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Burkitt Lymphoma
1
Advanced Haematological Malignancies
1
Interventions
Cyclophosphamide
125
Peripheral Blood Stem Cell Transplantation
84
fludarabine phosphate
81
Etoposide
73
Filgrastim
64
Mycophenolic Acid
63
Tacrolimus
57
Whole-Body Irradiation
55
Busulfan
52
Doxorubicin
50
Radiotherapy
48
Melphalan
48
Cyclosporine
47
Brentuximab Vedotin
45
Rituximab
39
Vinblastine
37
fludarabine
36
Granulocyte Colony-Stimulating Factor
36
Antilymphocyte Serum
35
Prednisone
33
Methotrexate
32
Vincristine
31
Gemcitabine
30
Dacarbazine
29
Bleomycin
29
Cytarabine
26
Carmustine
22
Bendamustine Hydrochloride
21
Sirolimus
18
Ifosfamide
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hodgkin Disease
×
acalabrutinib
×
Clear all
NCT02362035
2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2
Completed
161 enrolled
29 charts